Monopar reports ALXN1840 shows significant neurologic and global benefit in Phase 3 FoCus trial

Monopar Therapeutics

ALXN1840 achieved significant neurologic improvement on UWDRS Part III (p=0.006) vs SOC (p=0.435) over 48 weeks.
Global clinical improvement on CGI-I at Week 48 significantly greater with ALXN1840 vs SOC (p<0.001).
Favorable safety profile: drug-related SAEs in 4.9% of patients, no treatment-related deaths.
Results support planned NDA submission to FDA for ALXN1840 in mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.